Inventor · disambiguated record
Kwok-Kin Wong
Also filed as: WONG KWOK · WONG KWOK-KIN
18 granted patents·18 pending applications·44 citations·filing 2006–2025
91Inventor score
Top patents by PatentIndex Score
36 records- 0190US8168602B2Compositions, kits and methods for identification, assessment, prevention and therapy of cancerDEPINHO RONALD A·Filed 2006·Granted May 1, 2012·15 cites·7 claims
- 0289US10702527B2Combination therapy of transcription inhibitors and kinase inhibitorsDANA FARBER CANCER INST INC·Filed 2016·Granted Jul 7, 2020·5 cites·26 claims
- 0387US10472599B2Microfluidic cell culture of patient-derived tumor cell spheroidsDANA FARBER CANCER INST INC·Filed 2016·Granted Nov 12, 2019·5 cites·16 claims
- 0483US9616062B2Cyclin dependent kinase inhibitors and methods of useUNIV NORTH CAROLINA CHAPEL HILL·Filed 2013·Granted Apr 11, 2017·7 cites·17 claims
- 0580US11298354B2Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitorsDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 12, 2022·2 cites·11 claims
- 0679US10836722B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 17, 2020·1 cites·18 claims
- 0778US10385019B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Aug 20, 2019·2 cites·21 claims
- 0873US10947596B2Compositions and methods for identification, assessment, prevention, and treatment of cancer using NFS1 biomarkers and modulatorsDANA FARBER CANCER INST INC·Filed 2015·Granted Mar 16, 2021·2 cites·1 claims
- 0972US12336988B2Therapeutic targeting of KMT2D mutant lung squamous cell carcinoma through RTK-RAS signaling inhibitionUNIV NEW YORK·Filed 2022·Granted Jun 24, 2025·0 cites·3 claims
- 1069US9090693B2Use of anti-EGFR antibodies in treatment of EGFR mutant mediated diseaseWONG KWOK-KIN·Filed 2008·Granted Jul 28, 2015·2 cites·18 claims
- 1168US10501537B2Methods for treating cancerDANA FARBER CANCER INST INC·Filed 2015·Granted Dec 10, 2019·1 cites·13 claims
- 1267US11009508B2Methods of diagnosing and prognosing lung cancerDANA FARBER CANCER INST INC·Filed 2019·Granted May 18, 2021·0 cites·15 claims
- 1367US2025082648A1Compositions and methods for enhancing kras inhibitor or shp2 inhibitor efficacyUNIV NEW YORK·Filed 2024·Application pending·0 cites
- 1466US11446309B2Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitorsDANA FARBER CANCER INST INC·Filed 2014·Granted Sep 20, 2022·0 cites·6 claims
- 1566US2020399573A9Microfluidic cell culture of patient-derived tumor cell spheroidsDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 1666US2025332163A1Therapeutic targeting of kmt2d mutant lung squamous cell carcinoma through rtk-ras signaling inhibitionUNIV NEW YORK·Filed 2025·Application pending·0 cites
- 1766US2021094913A1Inhibitors of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 1863US2011319415A1Susceptibility to HSP90-InhibitorsTHOMAS ROMAN·Filed 2009·Application pending·0 cites
- 1962US9808461B2Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6DIROCCO DEREK P·Filed 2011·Granted Nov 7, 2017·2 cites·21 claims
- 2062US2024247074A1Therapeutic strategy for non-small cell lung cancer and other cancersUNIV NEW YORK·Filed 2024·Application pending·0 cites
- 2158US11944615B2Combination therapy for treatment of LKB1 deficient cancersUNIV NEW YORK·Filed 2021·Granted Apr 2, 2024·0 cites·13 claims
- 2258US2022356264A1Inhibition of atf7ip and setdb1 for cancer treatmentUNIV NEW YORK·Filed 2022·Application pending·0 cites
- 2358US2020338074A1Combination therapy of transcription inhibitors and kinase inhibitorsDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2457US2021100813A1Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitorsDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2555US11236082B2EZH2 inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Granted Feb 1, 2022·0 cites·24 claims
- 2654US2023114207A1The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancerDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2752US11865176B2Compositions and methods of modulating anti-tumor immunityDANA FARBER CANCER INST INC·Filed 2017·Granted Jan 9, 2024·0 cites·7 claims
- 2851US2013023420A1Susceptibility to hsp90-inhibitorsTHOMAS ROMAN·Filed 2012·Application pending·0 cites
- 2949US2014314791A1Methods of treating cancerDANA FARBER CANCER INST INC·Filed 2013·Application pending·0 cites
- 3048US2011119776A1Methods of diagnosing and prognosing lung cancerWONG KWOK-KIN·Filed 2008·Application pending·0 cites
- 3142US11624093B2Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor responseDANA FARBER CANCER INST INC·Filed 2015·Granted Apr 11, 2023·0 cites·21 claims
- 3239US2014378469A1Lkb1/stk11 deletion in melanoma and related methodsUNIV NORTH CAROLINA·Filed 2013·Application pending·0 cites
- 3338US2017306385A1Methods for discovering therapeutics that alter the stability of target proteinsDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 3438US2017292959A1Plasmids comprising internal ribosomal entry sites and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 3536US2012100100A1Cyclin dependent kinase inhibitors and methods of useSHARPLESS NORMAN E·Filed 2010·Application pending·0 cites
- 3633US2017115291A1Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor ResponseDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kwok-Kin Wong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →